Compare · ABBV vs IMMX
ABBV vs IMMX
Side-by-side comparison of AbbVie Inc. (ABBV) and Immix Biopharma Inc. (IMMX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and IMMX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $383.62B, about 651.3x IMMX ($589.0M).
- Over the past year, ABBV is up 15.9% and IMMX is up 301.2% - IMMX leads by 285.3 points.
- ABBV has been more active in the news (23 items in the past 4 weeks vs 17 for IMMX).
- ABBV has more recent analyst coverage (25 ratings vs 3 for IMMX).
- Company
- AbbVie Inc.
- Immix Biopharma Inc.
- Price
- $217.14+0.78%
- $8.43+0.72%
- Market cap
- $383.62B
- $589.0M
- 1M return
- +4.28%
- -11.22%
- 1Y return
- +15.90%
- +301.19%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2021
- News (4w)
- 23
- 17
- Recent ratings
- 25
- 3
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Immix Biopharma Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Latest ABBV
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- SEC Form 144 filed by AbbVie Inc.
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
Latest IMMX
- Immix Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Chang Nancy T was granted 6,250 shares, increasing direct ownership by 1% to 428,190 units (SEC Form 4)
- SEC Form 4 filed by CFO, President Morris Gabriel S
- Director Adams Helen C. was granted 6,250 shares, increasing direct ownership by 4% to 181,004 units (SEC Form 4)
- Director Marquet Magda was granted 6,250 shares, increasing direct ownership by 14% to 52,342 units (SEC Form 4)
- Director Ng Carey was granted 6,250 shares, increasing direct ownership by 31% to 26,250 units (SEC Form 4)
- Director Chudnovsky Yekaterina was granted 6,250 shares (SEC Form 4)
- Director Buchan Jane was granted 6,250 shares, increasing direct ownership by 28% to 28,705 units (SEC Form 4)
- SEC Form 4 filed by CEO and Chairman Rachman Ilya M
- Director Hsu Jason was granted 6,250 shares, increasing direct ownership by 0.70% to 899,250 units (SEC Form 4)